Physician profile
Mark Tratenberg
NPI 1780812461
$23,065.51
in general payments reported to CMS, 2019-2025
44 companies · $9,358 in 2025
The $9,358 reported for 2025 was more than what 89% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,590 · 2020: $735 · 2021: $1,213 · 2022: $2,008 · 2023: $2,735 · 2024: $4,427 · 2025: $9,358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,771 · Consulting Fee: $5,040 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,100 · Travel and Lodging: $355 · Education: $255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,770.60 |
| Consulting Fee | $5,040.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,100.00 |
| Travel and Lodging | $354.66 |
| Education | $254.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $5,802.83 | 2019-2025 | |
| Janssen Biotech, INC. | $4,941.64 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Abbvie INC. | $3,408.18 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $1,976.81 | 2019-2025 | Enbrel, Evenity, Prolia |
| Ucb, INC. | $1,234.62 | 2019-2025 | Cimzia, Bimzelx |
| Glaxosmithkline, LLC. | $1,011.82 | 2019-2025 | Benlysta |
| Genentech USA, INC. | $550.63 | 2019-2020 | |
| Lilly USA, LLC | $548.37 | 2019-2024 | Taltz |
| Genzyme Corporation | $321.81 | 2019-2025 | |
| Pfizer INC. | $301.00 | 2019-2023 | |
| Fresenius Kabi USA, LLC | $267.22 | 2023-2025 | Idacio |
| Ferring Pharmaceuticals INC. | $243.29 | 2019-2023 | Euflexxa |
| Cardinal Health 110 LLC | $200.00 | 2021-2022 | |
| Horizon Therapeutics Plc | $198.68 | 2019-2023 | Krystexxa |
| Ani Pharmaceuticals, INC. | $193.66 | 2022-2025 | Purified Cortrophin Gel |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Tratenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.